Exploring Roles of the Polysaccharide Capsule in Pathogenesis of Hypervirulent Acinetobacter baumannii Clinical Isolate Lac-4
-
Published:2023-12-20
Issue:1
Volume:13
Page:10
-
ISSN:2079-6382
-
Container-title:Antibiotics
-
language:en
-
Short-container-title:Antibiotics
Author:
Bjånes Elisabet1ORCID, Koh Truman1, Qayum Tariq1, Zurich Raymond1, McCabe Sinead1ORCID, Hampel Kegan1, Cartwright Lisa1, Nizet Victor12ORCID
Affiliation:
1. Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA 2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA
Abstract
The frequently multidrug-resistant bacterial pathogen Acinetobacter baumannii is a leading cause of nosocomial infections, including ventilator-associated pneumonia, such that the World Health Organization and US Centers for Disease Control and Prevention have declared it a top priority candidate for novel drug development. Nearly all clinical A. baumannii strains express a thick surface polysaccharide capsule that protects against desiccation, host defenses, and disinfectants. In this study, we investigated the contribution of the polysaccharide capsule to virulence caused by the A. baumannii clinical isolate Ab Lac-4, which is rare in its ability to cause pneumonia and disseminated sepsis in healthy mice. We assessed the role of the capsule in wildtype Lac-4 (WT) by generating a premature stop codon in wza, which codes for the polysaccharide export protein. The wza# mutant was hypersensitive to killing by complement, whole blood, and healthy human neutrophils compared to WT and a revertant mutant (wza-Rev). Furthermore, the wza# mutant was highly attenuated in murine sepsis and unable to disseminate from the lungs during pneumonia. This study reinforces the capsule as a key contributor to Ab Lac-4 hypervirulence.
Funder
National Institute of Health A.P. Giannini Foundation Postdoctoral Fellowship
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference40 articles.
1. Uncovering the mechanisms of Acinetobacter baumannii virulence;Harding;Nat. Rev. Microbiol.,2018 2. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii;Dijkshoorn;Nat. Rev. Microbiol.,2007 3. Cavallo, I., Oliva, A., Pages, R., Sivori, F., Truglio, M., Fabrizio, G., Pasqua, M., Pimpinelli, F., and Di Domenico, E.G. (2023). Acinetobacter baumannii in the critically ill: Complex infections get complicated. Front. Microbiol., 14. 4. Pogue, J.M., Zhou, Y., Kanakamedala, H., and Cai, B. (2022). Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect. Dis., 22. 5. Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629–655.
|
|